Italian pharmaceutical R&D excellence at the 33rd Congress of the European Association of Urology
Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results from a phase II trial evaluating efficacy and tolerability of Oncofid®P-B, an innovative Paclitaxel-Hyaluronan Bioconjugate targeted to cancer cells, in patients with primary or recurrent Ta G1-G2 papillary bladder cancer.
Fidia Presents New Data on HYMOVIS® , a Breakthrough in Viscoelastic Technology, at the American Orthopaedic Society for Sports Medicine 2016 Annual Meeting
HYMOVIS® is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties; new data demonstrating long-term benefits of Hymovis® in alleviating osteoarthritis knee pain and stiffness and improving physical function and quality of life will be presented.
PARSIPPANY, N.J., July 5, 2016 – Fidia Farmaceutici S.p.A., a world leader